Detection of CD5 in B-cell chronic lymphoproliferative diseases by flow cytometry: a strong expression in B-cell chronic lymphocytic leukemia

Cavalcanti, Geraldo Barroso; Sales, Valéria Soraya de Farias; Silva, Dany Geraldo Kramer Cavalcanti e; Lopes, M. C.; Paiva, Aldair de Souza; Fonseca, Henrique Eduardo Macedo da; Júnior, Francisco Fernandes do Nascimento; Fernandes, Maria Zélia

doi:10.1590/s0102-86502005000700011

Cited by 1 publication

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The membrane phenotype of the B-PLL is quite distinct from that of B-CLL The expression of CD5+, CD19+, CD23+and the absence of FMC7 surface markers are routinely used as diagnostic criteria in patients with B-CLL [15,25]. In addition, the absence of expression of FMC7 is one of the most reliable markers that differentiated B-CLL from other B cell neoplasms [25] and, moreover, CD5 negativity can help distinguish between B-CLL and B-PLL [26]. The CD23 antigen negatively correlates with prolymphocyte infiltration of the BM and PB lymphocyte counts [27].…”

Section: Discussionmentioning

confidence: 99%

Possible prognostic value of nucleolar morphology in pathologic cells of B-chronic lymphocytic leukemia

Klobusická

Kusenda²,

Stevulova³

et al. 2010

neo

View full text Add to dashboard Cite

B-cell chronic lymphocytic leukemia (B-CLL) represents a heterogeneous disease with a very variable outcome. The reliable prognosis of this disease at the time of initial diagnosis is difficult to predict. The purpose of this preliminary study was to utilize the nucleolar morphology and to investigate the incidence of main nucleolar types in leukemic lymphocytes in B-CLL patients to assess their possible predictive value for the disease outcome, in correlation with immunophenotype parameters. The evaluation of nucleolar morphology of pathologic lymphocytes was performed at diagnosis and during the course of disease. Median follow up period of patients was 16.4 months (range from 2 to 32 months) from diagnosis. The nucleoli were visualized by a simple cytochemical demonstration of RNA and the proportion of main nucleolar types in pathologic lymphocyte population infiltrating bone marrow of 84 patients suffering from B-CLL was analyzed. The presence of ring shaped and compact nucleoli in leukemic lymphocytes divided patients into two subgroups with different outcome of the disease. Malignant lymphocytes of the majority of patients (Group 1, 71 patients, 84.5%) mostly contained ring shaped nucleoli. These patients were in stable phase and did not require any treatment during the follow up. The population of leukemic cells of a small group of B-CLL patients (Group 2, 13 patients, 15.4%) was characterized by the presence of various proportions of pathologic lymphocytes with one large compact nucleolus.Different response to the therapy discriminated the B-CLL patients whose leukemic lymphocytes revealed evident compact nucleoli at presentation, to next two subsets. Four of these patients (Group 2, 4/13, 31%) appeared to be resistant to chemotherapy, others (9/13, 69%) showed response to therapy, though the response time was variable. Leukemic cells with compact nucleolus morphologically resembled prolymphocytes, but hematologically and immunophenotypically did not fulfill the diagnostic criteria for prolymphocyte population. None of our B-CLL patients had the signs of transformation to prolymphocytic or other type of B cell neoplasms during the follow up. Our results indicate the possibility of relationship between the presence of malignant lymphocytes with compact nucleoli and unfavorable outcome in patients with B-CLL. The simplicity and utility of the nucleolar test as a possible prognostic parameter may help to identify the subset of patients with early B-CLL disease that will run a more progressive course.

show abstract

Section: Discussionmentioning

confidence: 99%